<DOC>
	<DOCNO>NCT01053897</DOCNO>
	<brief_summary>The primary objective study ass whether intradermal injection GBT009 along full thickness incision follow surgery result improvement scar appearance .</brief_summary>
	<brief_title>Study GBT009 Treatment Incisional Wounds Following Breast Reconstruction Surgery</brief_title>
	<detailed_description />
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<criteria>Subjects must meet follow criterion consider eligible participate study : female 18 70 year age , inclusive body mass index ≤ 32 kg/m2 body weight 50 95 kg , inclusive schedule mastectomy breast reconstruction surgery use abdominal flap technique woman diagnose breast cancer , standard care treatment breast cancer prior surgery standard care treatment breast cancer surgery subject childbearing potential , surgically sterile use insertable , injectable , transdermal , combination oral contraceptive approve FDA completion study negative result serum pregnancy test do administration study medication ( woman postmenopausal [ menses least 2 year ] also eligible participate ) able understand study procedure , agree participate study program , voluntarily provide write informed consent Subjects meet follow criterion exclude participate study : clinically significant laboratory abnormality screen , determine investigator sponsor 's medical monitor , history clinical manifestation significant renal , hepatic , cardiovascular , metabolic , neurologic , psychiatric , coagulopathic disorder condition would preclude participation study receive treatment severe , uncontrolled inflammatory disease allergic condition within three month screen life expectancy ≤ 2 year history alcoholism drug addiction abuse within 5 year evidence clinically significant abnormality upon evaluation 12 lead ECG evidence past present clinically significant medical condition , include skin disease , would impair wound heal history keloid scar formation exist scar abdominal area study would interfere efficacy assessment history ( within past 5 year ) active malignancy , breast cancer breast cancer stag Stage IIIB , IIIC IV receive cytotoxic agent treat radiation within 90 day screen and/or , opinion investigator , likely require treatment 30 day period follow administration study medication receive anticoagulation medication within 5 day dose study medication participate study involve investigational product within 30 day dose study medication routinely use tobacco product within 6 month precede study period</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>GBT009</keyword>
	<keyword>incisional scar</keyword>
	<keyword>breast reconstruction</keyword>
</DOC>